India Faces AMR Earlier Than the World, And Why Its Genomic Diagnostics Could Lead the Response

Antimicrobial resistance is not a 2050 problem for India. Hospitals across India are already reporting carbapenem-resistant infections at alarming rates. A recent study from a tertiary care centre in South India found that nearly one in four Gram-negative bacterial cultures were carbapenem-resistant, with pathogens like Acinetobacter baumannii and Klebsiella pneumoniae showing resistance rates as high as 48% and 38.6%, respectively. Even more concerning is that almost half of these resistant infections carried multiple carbapenemase genes simultaneously, which shows a genetic complexity that severely limits treatment options.

These findings confirm what many clinicians are already experiencing on the ground: that in India, AMR is already entrenched, dynamic, and spreading fast.

Why India Is Ahead of the AMR Curve

India’s AMR trajectory is accelerated by scale and exposure. A high infectious disease burden means that antibiotics are used frequently and urgently. In many clinical settings, empirical therapy remains the default because waiting for culture results is not always an option. This creates ideal conditions for resistant microbes to emerge, spread, and stabilise.

Add to this the reality of dense hospital environments, high patient turnover, and widespread colonisation with resistant bacteria even among asymptomatic individuals, and it becomes clear why India’s AMR challenge looks different from that of other countries.

It has become essential for India to develop its genomics capabilities. Next-generation sequencing allows drug resistance to be detected at the gene level; instead of asking which bacteria grew, genomics asks which resistance mechanisms already exist. And this shift matters. It enables us to move from probability-based prescribing to evidence-based decisions, and to detect emerging patterns before they can become outbreaks.

Introducing infexn®-NGS, India’s Genomics-Driven AMR Solution

infexn®-NGS by HaystackAnalytics was built for precisely this gap. It uses high-resolution sequencing to reveal the entire resistance profile of a pathogen in just one test. That means that doctors and infectious disease teams can identify multi-drug resistant organisms even in culture-negative samples, be aware of the early warning signals for superbug outbreaks in hospitals, and directly refine antimicrobial stewardship.

AMR is evolving faster than traditional workflows are able to track. But infexn®-NGS helps shift the response to proactive control.

A Future Where India Sets the Standard

If India adopts genomics-guided diagnostics at scale, it can rebuild empirical therapy into evidence-based therapy and reduce the unnecessary use of broad-spectrum antibiotics, which is one of the largest contributors to AMR in the country. If we set a new standard for antimicrobial stewardship that is driven by genomic surveillance, this can also inform national AMR policies with backing from high-quality data. And most importantly, we can prevent outbreaks before they unfold. This matters not just for us, but for future generations to come.

India does not have the luxury of waiting until 2050 to take action against antimicrobial resistance. But it does have the opportunity to become the global model for preventing antimicrobial resistance together.

So whether you are a doctor, infectious disease specialist, or policymaker, it is clear that now is the time to invest in genomic diagnostics and surveillance. Learn more about infexn®-NGS by HaystackAnalytics today.